Should You Buy Chemomab Therapeutics Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Chemomab Therapeutics Ltd. (CMMB) sits in the bottom tier of our quality coverage with a score of 2.2/10. While a weak quality score suggests operational challenges, our valuation models assess if the market has over-discounted the stock at $1.47.
The short answer: 5 of 9 CirclFi valuation models project upside for Chemomab Therapeutics Ltd. (CMMB) at $1.47 — the model consensus leans bullish, with a Quality Score of 2.2/10 and Value-Trap risk of 6/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $2.41 (+64.0% upside)
- According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $2.41 (+64.0%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously.
- Industry tailwind: late-stage pipeline catalysts could provide meaningful support for Chemomab Therapeutics Ltd.'s revenue and margin trajectory in the Pharmaceutical Preparations space.
The Bear Case
Target: $0.16 (-88.9%)
- According to the CirclFi Quality of Company (QOC) framework, Chemomab Therapeutics Ltd.'s rating of 2.2/10 indicates below-average quality, raising questions about sustainable earnings levels.
- According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $0.16 (-88.9%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +152.8% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
- Industry headwind: regulatory rejection risk represents a meaningful risk for Chemomab Therapeutics Ltd. and its Pharmaceutical Preparations peers.
The Bottom Line
Our models don't have a clear verdict on Chemomab Therapeutics Ltd.. At $1.47 vs. $1.27 composite fair value, the average upside of -13.9% masks significant model disagreement (+152.8% spread). With quality at 2.2/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Chemomab Therapeutics Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy CMMB stock right now?
Based on CirclFi's multi-model analysis, 5 of 9 models see upside for CMMB at $1.47. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 2.2/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Chemomab Therapeutics Ltd.?
Key risks include: a below-average Quality Score of 2.2/10, indicating fundamental weakness; wide model disagreement (1375% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.
How does CMMB compare to its competitors?
Among Pharmaceutical Preparations peers, CMMB holds a Quality Score of 2.2/10. Comparable companies include CPRX (QOC 10.0), HRMY (QOC 10.0), NVO (QOC 10.0). The relative ranking helps investors identify whether CMMB offers better fundamental quality than alternatives in the same sector.
Is CMMB a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CMMB's Quality Score of 2.2/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy CMMB at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $0.16 to $2.41. At $1.47, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CMMB.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad